(Q37778608)

23 August 2017

1 reference

title

Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation (English)

1 reference

23 August 2017

0 references

8

Andrew Blauvelt

1 reference

23 August 2017

Samuel Bremmer

1

1 reference

23 August 2017

Sylvia Hsu

3

1 reference

23 August 2017

Melodie Young

6

1 reference

23 August 2017

National Psoriasis Foundation

9

1 reference

23 August 2017

Abby S. Van Voorhees

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692722

18 June 2024

Neil J. Korman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692722

18 June 2024

Mark G. Lebwohl

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692722

18 June 2024

Bruce F. Bebo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20692722

18 June 2024

language of work or name

English

0 references

publication date

7 August 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0190962209015060?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

https://api.elsevier.com/content/article/PII:S0190962209015060?httpAccept=text/plain

18 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Journal of the American Academy of Dermatology

18 June 2024

published in

1 reference

23 August 2017

volume

63

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

1058-1069

1 reference

Metabolic disorders in patients with psoriasis and psoriatic arthritis

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review

18 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients

18 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Obesity and the skin: Skin physiology and skin manifestations of obesity

18 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Disease concomitance in psoriasis.

18 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study.

18 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Prevalence of cardiovascular risk factors in patients with psoriasis

18 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Association between psoriasis and the metabolic syndrome. A cross-sectional study

18 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Impact of obesity and smoking on psoriasis presentation and management

18 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis

18 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome.

18 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Relationship of psoriasis severity to obesity using same-gender siblings as controls for obesity

18 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

The prevalence of psoriasis in the world

18 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Clinical guidelines: developing guidelines

18 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

18 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

18 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

18 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

18 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Efficacy of etanercept in an integrated multistudy database of patients with psoriasis

18 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Safety and efficacy of alefacept in elderly patients and other special populations

18 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.

18 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients

18 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury

18 June 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment

18 June 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent

18 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment

18 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Liver biopsies and methotrexate: a time for reconsideration?

18 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Effect of obesity on cyclosporine trough concentrations in psoriasis patients

18 June 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Psoriasis is associated with lipid abnormalities at the onset of skin disease

18 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Dietary behaviour in psoriatic patients

18 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Additional studies on psoriasis in the tropics and in starvation camps.

18 June 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Jejunoileal bypass and psoriasis

18 June 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Remission of psoriasis after open gastric bypass

18 June 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity

18 June 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II.

18 June 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

18 June 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase

18 June 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

18 June 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss

18 June 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Plasma concentrations of soluble TNF-alpha receptors in obese subjects

18 June 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

18 June 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Tumor necrosis factor alpha: a key component of the obesity-diabetes link

18 June 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output

18 June 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Insulin resistance: an adaptation for weight maintenance

18 June 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes

18 June 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation.

18 June 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis

18 June 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis

18 June 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease.

18 June 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Serum lipid and apolipoprotein levels in patients with psoriasis

18 June 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease

18 June 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study

18 June 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Psoriasis patients show signs of insulin resistance

18 June 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses

18 June 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study.

18 June 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Statistical association between psoriasis and diabetes: Further results

18 June 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Risk of Myocardial Infarction in Patients With Psoriasis

18 June 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Lipid profile, insulin secretion, and insulin sensitivity in psoriasis

18 June 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression

18 June 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes

18 June 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters

18 June 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.

18 June 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Resistin, central obesity, and type 2 diabetes.

18 June 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

18 June 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin

18 June 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.

18 June 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

The effect of weight on the efficacy of biologic therapy in patients with psoriasis

18 June 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines

18 June 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

AJC editor's consensus: psoriasis and coronary artery disease.

18 June 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

The risk of stroke in patients with psoriasis

18 June 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis

18 June 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Methotrexate guidelines--revised

18 June 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Ciclosporin in psoriasis clinical practice: an international consensus statement

18 June 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.

18 June 2024

86

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis

18 June 2024

87

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol

18 June 2024

88

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis

18 June 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.JAAD.2009.09.053

18 June 2024

Identifiers

1 reference

23 August 2017

1 reference